Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial

Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial is a phase 2, interventional study registered as NCT07774754 by Sun Yat-sen University, with a registry enrolment figure of 18 participants, started 2026-09-01 and due to reach its primary completion in 2028-01-01. Interventions recorded: Drug：sintilimab; Drug：Capecitabine; Drug：Suvemcitug; Radiation: Neoadjuvant Radiotherapy. Conditions listed: Rectal Cancer. Primary outcome: Serious Adverse Effects of Neoadjuvant Therapy. Colorectal eligibility wording from the registry: "3\) Histologically confirmed rectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.